Substance P Drives Cancer Progression in Head and Neck Tumors via NK1 Receptor | Research

The takeaway

The neuropeptide substance P promotes head and neck cancer progression through NK1 receptor activation, driving cell proliferation, migration, and chronic inflammation that transitions to neoplastic transformation.

1.5M cases/year
Head and neck cancer is a major global health burden, and substance P/NK1R may drive the inflammatory transition to malignancy in these tissues

What the researchers found

Substance P and NK1R upregulate cell proliferation, cell migration, and chronic inflammation in head and neck cancers, playing a role in the transition from chronic mucosal inflammation to neoplastic transformation and progression.

Why it matters

If substance P drives the inflammatory-to-cancer transition in the head and neck, NK1R antagonists (substance P blockers) could potentially prevent or treat these cancers — a completely new therapeutic approach.

The numbers in context

~1.5 million new cases/year; ~500,000 deaths/year; SP/NK1R upregulates proliferation, migration, inflammation; relevant to laryngeal and oral squamous cell carcinomas

How the study worked

Narrative review of published literature on the substance P/NK1R system in chronic inflammation and carcinogenesis of the head and neck region.

Who was studied

Review of SP/NK1R in head and neck chronic inflammation and cancer

What this study cannot tell us

Narrative review with no new experimental data. Direct causal evidence for SP driving cancer in humans is limited. NK1R antagonists have not been tested as anticancer agents in head and neck cancer clinical trials.

How to read the evidence

Not applicable (narrative review). Based on a combination of in vitro, animal, and clinical observational data.

When this study was published

Published in 2021. Research on NK1R antagonists as potential anticancer agents continues.

The bigger picture

The role of neuropeptides in cancer is increasingly recognized. Substance P's involvement in inflammation-to-cancer transitions suggests that the nervous system plays a more active role in tumor development than previously understood, opening new avenues for cancer prevention.

Questions still open

Could NK1R antagonists prevent head and neck cancer in people with chronic oral/laryngeal inflammation?
Is substance P a viable biomarker for identifying patients at risk of malignant transformation?
Would combining NK1R blockers with standard cancer treatments improve outcomes?

Common questions

How does substance P promote cancer?

Substance P activates the NK1 receptor, which triggers cell multiplication, helps cancer cells migrate, and sustains chronic inflammation. In the mouth and throat, this can drive the transition from chronic inflammation to precancerous and cancerous changes.

Could blocking substance P prevent head and neck cancer?

Theoretically, NK1R antagonists could interrupt the inflammation-to-cancer transition. Drugs that block NK1R already exist for other conditions (like nausea), but they haven't been tested as cancer prevention agents in clinical trials yet.

Read the original research

Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature.

International journal of environmental research and public health, 19(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Esteban, Francisco; Ramos-García, Pablo; Muñoz, Miguel; González-Moles, Miguel Ángel. (2021). Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature.. International journal of environmental research and public health, 19(1). https://doi.org/10.3390/ijerph19010375